These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33838596)

  • 1. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.
    Salvatore L; Bria E; Sperduti I; Hinke A; Hegewisch-Becker S; Aparicio T; Le Malicot K; Boige V; Koeberle D; Baertschi D; Dietrich D; Tortora G; Arnold D
    Cancer Treat Rev; 2021 Jun; 97():102202. PubMed ID: 33838596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis.
    Ma H; Wu X; Tao M; Tang N; Li Y; Zhang X; Zhou Q
    Medicine (Baltimore); 2019 Dec; 98(50):e18227. PubMed ID: 31852082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis.
    Stein A; Schwenke C; Folprecht G; Arnold D
    Clin Colorectal Cancer; 2016 Jun; 15(2):e29-39. PubMed ID: 26781523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
    Manfredi S; Turpin A; Malka D; Barbier E; Laurent-Puig P; Zaanan A; Dahan L; Lièvre A; Phelip JM; Michel P; Hautefeuille V; Legoux JL; Lepage C; Tougeron D; Aparicio T
    Dig Liver Dis; 2020 Oct; 52(10):1143-1147. PubMed ID: 32747302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
    Stahler A; Modest DP; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Kurreck A; Heinrich K; Gießen-Jung C; Neumann J; Kirchner T; Jung A; Stintzing S; Heinemann V
    Eur J Cancer; 2022 Sep; 173():194-203. PubMed ID: 35940054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
    Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).
    Aparicio T; Ghiringhelli F; Boige V; Le Malicot K; Taieb J; Bouché O; Phelip JM; François E; Borel C; Faroux R; Dahan L; Jacquot S; Genet D; Khemissa F; Suc E; Desseigne F; Texereau P; Lepage C; Bennouna J;
    J Clin Oncol; 2018 Mar; 36(7):674-681. PubMed ID: 29346040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
    Baraniskin A; Buchberger B; Pox C; Graeven U; Holch JW; Schmiegel W; Heinemann V
    Eur J Cancer; 2019 Jan; 106():37-44. PubMed ID: 30476731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
    Heinrich K; Modest DP; Ricard I; Fischer von Weikersthal L; Decker T; Kaiser F; Graeven U; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Giessen-Jung C; Stahler A; Michl M; Held S; Jung A; Kirchner T; Stintzing S; Heinemann V
    Eur J Cancer; 2021 Apr; 147():128-139. PubMed ID: 33647548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.
    You XH; Jiang YH; Fang Z; Sun F; Li Y; Wang W; Xia ZJ; Wang XZ; Ying HQ
    ESMO Open; 2020 Mar; 4(Suppl 2):. PubMed ID: 32132090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
    Cremolini C; Marmorino F; Bergamo F; Aprile G; Salvatore L; Masi G; Dell'Aquila E; Antoniotti C; Murgioni S; Allegrini G; Borelli B; Gemma D; Casagrande M; Granetto C; Delfanti S; Di Donato S; Schirripa M; Sensi E; Tonini G; Lonardi S; Fontanini G; Boni L; Falcone A
    Eur J Cancer; 2019 Mar; 109():175-182. PubMed ID: 30735919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
    Goey KKH; Elias SG; Hinke A; van Oijen MGH; Punt CJA; Hegewisch-Becker S; Arnold D; Koopman M
    Br J Cancer; 2017 Dec; 117(12):1768-1776. PubMed ID: 29123255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
    Moriwaki T; Gosho M; Sugaya A; Yamada T; Yamamoto Y; Hyodo I
    Cancer Res Treat; 2021 Jul; 53(3):703-713. PubMed ID: 33285056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.
    Cao D; Zheng Y; Xu H; Ge W; Xu X
    Sci Rep; 2019 Dec; 9(1):20326. PubMed ID: 31889159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
    Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.
    Artaç M; Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2019 Jun; 50(2):214-220. PubMed ID: 29302856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.